Akero Therapeutics (AKRO) News Today $51.84 +1.26 (+2.49%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$50.52 -1.32 (-2.54%) As of 02/21/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period The Healthcare Sector and its Dynamics in the Stock MarketFebruary 19 at 3:49 PM | uk.finance.yahoo.comAkero Therapeutics, Inc. (AKRO): the Best Performing Healthcare Stock So Far in 2025February 19 at 3:49 PM | msn.comAnalysts Set Akero Therapeutics, Inc. (NASDAQ:AKRO) Target Price at $75.86February 19 at 2:07 AM | americanbankingnews.comAkero Therapeutics, Inc. (NASDAQ:AKRO) Short Interest Up 8.4% in JanuaryAkero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) saw a significant growth in short interest in January. As of January 31st, there was short interest totalling 3,630,000 shares, a growth of 8.4% from the January 15th total of 3,350,000 shares. Based on an average trading volume of 1,150,000 shares, the short-interest ratio is currently 3.2 days.February 17, 2025 | marketbeat.comAkero Therapeutics, Inc. (NASDAQ:AKRO) Sees Significant Growth in Short InterestFebruary 17, 2025 | americanbankingnews.comAkero Therapeutics, Inc. (NASDAQ:AKRO) Given Average Recommendation of "Buy" by BrokeragesAkero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) has been assigned an average recommendation of "Buy" from the nine ratings firms that are currently covering the firm, Marketbeat reports. Nine investment analysts have rated the stock with a buy recommendation. The average 1-year price targFebruary 14, 2025 | marketbeat.comInsider Selling: Akero Therapeutics, Inc. (NASDAQ:AKRO) CEO Sells 30,000 Shares of StockAkero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) CEO Andrew Cheng sold 30,000 shares of the firm's stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $52.73, for a total transaction of $1,581,900.00. Following the completion of the sale, the chief executive officer now owns 686,062 shares in the company, valued at approximately $36,176,049.26. The trade was a 4.19 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.February 11, 2025 | marketbeat.comabrdn plc Grows Position in Akero Therapeutics, Inc. (NASDAQ:AKRO)abrdn plc grew its stake in Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 118.7% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 269,782 shares of the company's stock after purchasing an additional 146,424 shares duFebruary 9, 2025 | marketbeat.comAkero Therapeutics, Inc. (NASDAQ:AKRO) Insider Sells $1,059,562.50 in StockFebruary 8, 2025 | insidertrades.comAkero Therapeutics' chief scientific officer sells $1.06 million in stockFebruary 7, 2025 | msn.comAkero Therapeutics, Inc. (NASDAQ:AKRO) Insider Sells $1,059,562.50 in StockAkero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) insider Timothy Rolph sold 18,750 shares of Akero Therapeutics stock in a transaction dated Wednesday, February 5th. The shares were sold at an average price of $56.51, for a total transaction of $1,059,562.50. Following the completion of the sale, the insider now owns 170,237 shares in the company, valued at approximately $9,620,092.87. This trade represents a 9.92 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.February 7, 2025 | marketbeat.comAkero Therapeutics, Inc. (NASDAQ:AKRO) Director G. Walmsley Graham Acquires 200,000 SharesAkero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) Director G. Walmsley Graham purchased 200,000 shares of the business's stock in a transaction on Thursday, January 30th. The shares were bought at an average cost of $48.00 per share, with a total value of $9,600,000.00. Following the acquisition, the director now directly owns 1,000,000 shares of the company's stock, valued at $48,000,000. This trade represents a 25.00 % increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.February 7, 2025 | marketbeat.comAkero Therapeutics, Inc. (NASDAQ:AKRO) COO Sells $538,100.00 in StockFebruary 6, 2025 | insidertrades.comAkero Therapeutics, Inc. (NASDAQ:AKRO) COO Jonathan Young Sells 10,000 Shares of StockAkero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) COO Jonathan Young sold 10,000 shares of the stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $53.81, for a total value of $538,100.00. Following the transaction, the chief operating officer now owns 251,147 shares in the company, valued at $13,514,220.07. This trade represents a 3.83 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.February 5, 2025 | marketbeat.comAkero Therapeutics COO Jonathan Young sells shares worth $538,060February 5, 2025 | msn.comWhy Akero Therapeutics Inc (AKRO) Is Skyrocketing So Far In 2025February 3, 2025 | msn.comAkero Therapeutics Inc. (AKRO): Among The Stocks That Started The Year On A HighFebruary 3, 2025 | msn.comThis Stock Just Doubled in 1 Day -- Is It Still a Buy?February 2, 2025 | fool.comAkero Therapeutics price target raised to $109 from $42 at UBSJanuary 31, 2025 | markets.businessinsider.comUBS Group Issues Positive Forecast for Akero Therapeutics (NASDAQ:AKRO) Stock PriceUBS Group raised their price target on shares of Akero Therapeutics from $42.00 to $109.00 and gave the company a "buy" rating in a research report on Friday.January 31, 2025 | marketbeat.comB of A Securities Upgrades Akero Therapeutics (AKRO)January 30, 2025 | msn.comAkero raised to Buy at Bank of America after liver drug dataJanuary 30, 2025 | msn.comAkero Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional SharesJanuary 30, 2025 | globenewswire.comAkero Therapeutics upgraded to Buy from Neutral at BofAJanuary 30, 2025 | markets.businessinsider.comAkero Therapeutics (NASDAQ:AKRO) Raised to Buy at Bank of AmericaBank of America raised Akero Therapeutics from a "neutral" rating to a "buy" rating and upped their price target for the company from $35.00 to $63.00 in a report on Thursday.January 30, 2025 | marketbeat.comInsider Selling: Akero Therapeutics, Inc. (NASDAQ:AKRO) VP Sells 5,000 Shares of StockJanuary 30, 2025 | insidertrades.comPatrick Lamy Sells 5,000 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) StockAkero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) VP Patrick Lamy sold 5,000 shares of Akero Therapeutics stock in a transaction dated Monday, January 27th. The shares were sold at an average price of $57.03, for a total transaction of $285,150.00. Following the completion of the sale, the vice president now owns 33,492 shares in the company, valued at approximately $1,910,048.76. This trade represents a 12.99 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.January 29, 2025 | marketbeat.comTimothy Rolph Sells 31,250 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) StockAkero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) insider Timothy Rolph sold 31,250 shares of the company's stock in a transaction that occurred on Monday, January 27th. The stock was sold at an average price of $55.77, for a total transaction of $1,742,812.50. Following the completion of the sale, the insider now directly owns 170,237 shares of the company's stock, valued at $9,494,117.49. The trade was a 15.51 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.January 29, 2025 | marketbeat.comJ.P. Morgan Keeps Their Buy Rating on Akero Therapeutics (AKRO)January 29, 2025 | markets.businessinsider.comJefferies raises Akero Therapeutics price target to $75January 29, 2025 | msn.comAkero Therapeutics (NASDAQ:AKRO) Trading 4.8% Higher After Analyst UpgradeAkero Therapeutics (NASDAQ:AKRO) Trading 4.8% Higher on Analyst UpgradeJanuary 29, 2025 | marketbeat.comWhat is HC Wainwright's Forecast for AKRO FY2029 Earnings?Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) - Research analysts at HC Wainwright issued their FY2029 earnings per share estimates for shares of Akero Therapeutics in a report released on Monday, January 27th. HC Wainwright analyst E. Arce expects that the company will earn $5.58 per sharJanuary 29, 2025 | marketbeat.comMorgan Stanley Raises Akero Therapeutics (NASDAQ:AKRO) Price Target to $96.00Morgan Stanley lifted their target price on shares of Akero Therapeutics from $46.00 to $96.00 and gave the company an "overweight" rating in a report on Tuesday.January 29, 2025 | marketbeat.comAkero Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded WarrantsJanuary 28, 2025 | globenewswire.comAkero Therapeutics: Promising SYMMETRY Trial Results Position Efruxifermin for Market SuccessJanuary 28, 2025 | markets.businessinsider.comSome Good MASH/NASH News From Akero TherapeuticsJanuary 28, 2025 | seekingalpha.comAkero Therapeutics price target raised to $80 from $65 at CitiJanuary 28, 2025 | markets.businessinsider.comWhy Akero Therapeutics Inc. (AKRO) Surged on MondayJanuary 28, 2025 | msn.comAkero Therapeutics (NASDAQ:AKRO) Stock Price Expected to Rise, Morgan Stanley Analyst SaysMorgan Stanley boosted their target price on shares of Akero Therapeutics from $46.00 to $96.00 and gave the company an "overweight" rating in a report on Tuesday.January 28, 2025 | marketbeat.comAkero Therapeutics (NASDAQ:AKRO) Shares Gap Up Following Analyst UpgradeAkero Therapeutics (NASDAQ:AKRO) Shares Gap Up Following Analyst UpgradeJanuary 28, 2025 | marketbeat.comCitigroup Increases Akero Therapeutics (NASDAQ:AKRO) Price Target to $80.00Citigroup raised their target price on shares of Akero Therapeutics from $65.00 to $80.00 and gave the company a "buy" rating in a report on Tuesday.January 28, 2025 | marketbeat.comCanaccord Genuity Group Forecasts Strong Price Appreciation for Akero Therapeutics (NASDAQ:AKRO) StockCanaccord Genuity Group upped their target price on Akero Therapeutics from $56.00 to $73.00 and gave the company a "buy" rating in a research report on Tuesday.January 28, 2025 | marketbeat.comAkero Therapeutics MASH data ‘best-case-scenario,’ says CitiJanuary 27, 2025 | markets.businessinsider.comAkero Therapeutics Announces Proposed Public Offering of Common StockJanuary 27, 2025 | globenewswire.comAkero Therapeutics’ efruxifermin shows efficacy in Phase 2b cirrhosis trialJanuary 27, 2025 | markets.businessinsider.comAkero's Efruxifermin Shows Cirrhosis Reversal In MASH Patients, Stock Soars In Pre-MarketJanuary 27, 2025 | markets.businessinsider.comAkero stock soars 115% on positive data for MASH drugJanuary 27, 2025 | seekingalpha.comAKRO stock hits 52-week high, soaring to $56.86January 27, 2025 | msn.comAkero Therapeutics Stock Doubles on Liver Disease Drug Trial ResultsJanuary 27, 2025 | investopedia.comAkero Therapeutics (NASDAQ:AKRO) Price Target Raised to $72.00HC Wainwright raised their price objective on Akero Therapeutics from $50.00 to $72.00 and gave the company a "buy" rating in a report on Monday.January 27, 2025 | marketbeat.com Get Akero Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AKRO and its competitors with MarketBeat's FREE daily newsletter. Email Address AKRO Media Mentions By Week AKRO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AKRO News Sentiment▼0.890.60▲Average Medical News Sentiment AKRO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AKRO Articles This Week▼68▲AKRO Articles Average Week Get Akero Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AKRO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Genmab A/S News Intra-Cellular Therapies News Viatris News Moderna News Dr. Reddy's Laboratories News Vaxcyte News Sarepta Therapeutics News Qiagen News Ascendis Pharma A/S News Roivant Sciences News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AKRO) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredWhat is this southern state hiding?The financial press had a field day this week after President Donald Trump and Department of Government Effici...Stansberry Research | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | SponsoredHow to trade Executive Order 14154Trump’s pen must be running out of ink… Since he returned to office he’s signed more than 50 Executive Orde...Porter & Company | SponsoredMajor AI announcement for 2025BIG NEWS: “Market Wizard” Larry Benedict Releases a Whole New Way to Trade AI StocksBrownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akero Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Akero Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
